A Randomized, Parallel-controlled, Open-label, Multicenter Phase III Clinical Study to Compare the Efficacy and Safety of D-0502 With Fulvestrant in Patients With Previously Treated ER-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
Latest Information Update: 09 May 2025
At a glance
- Drugs Taragarestrant (Primary) ; Fulvestrant
- Indications HER2 negative breast cancer
- Focus Registrational; Therapeutic Use
- Sponsors InventisBio
Most Recent Events
- 09 May 2025 New trial record